Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 28

Cited In for PubMed (Select 16494585)


Hydrogen sulphide protects against NSAID-enteropathy through modulation of bile and the microbiota.

Blackler RW, Motta JP, Manko A, Workentine M, Bercik P, Surette MG, Wallace JL.

Br J Pharmacol. 2015 Feb;172(4):992-1004. doi: 10.1111/bph.12961. Epub 2014 Nov 24.


Importance of adherence to gastroprotection during cyclooxygenase 2 inhibitor treatment.

Gargallo CJ, Lanas A.

Ann Gastroenterol. 2013;26(3):270-271. No abstract available.


Sodium alginate ameliorates indomethacin-induced gastrointestinal mucosal injury via inhibiting translocation in rats.

Yamamoto A, Itoh T, Nasu R, Nishida R.

World J Gastroenterol. 2014 Mar 14;20(10):2641-52. doi: 10.3748/wjg.v20.i10.2641.


The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage.

Scheiman JM.

Arthritis Res Ther. 2013;15 Suppl 3:S5. doi: 10.1186/ar4177. Epub 2013 Jul 24. Review.


Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients--focus on esomeprazole.

Tang RS, Wu JC.

Clin Interv Aging. 2013;8:1433-43. doi: 10.2147/CIA.S41350. Epub 2013 Oct 25. Review.


Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs.

Sugano K, Kinoshita Y, Miwa H, Takeuchi T; Esomeprazole NSAID Preventive Study Group.

BMC Gastroenterol. 2013 Mar 26;13:54. doi: 10.1186/1471-230X-13-54.


Adherence to the preventive strategies for nonsteroidal anti-inflammatory drug- or low-dose aspirin-induced gastrointestinal injuries.

Fujita T, Kutsumi H, Sanuki T, Hayakumo T, Azuma T.

J Gastroenterol. 2013 May;48(5):559-73. doi: 10.1007/s00535-013-0771-8. Epub 2013 Mar 5. Review.


Piroxicam-β-cyclodextrin: a GI safer piroxicam.

Scarpignato C.

Curr Med Chem. 2013;20(19):2415-37. Review.


Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence.

Blackler R, Syer S, Bolla M, Ongini E, Wallace JL.

PLoS One. 2012;7(4):e35196. doi: 10.1371/journal.pone.0035196. Epub 2012 Apr 9.


Aspirin for the older person: report of a meeting at the Royal Society of Medicine, London, 3rd November 2011.

Armitage J, Cuzick J, Elwood P, Longley M, Perkins A, Spencer K, Turner H, Porch S, Lyness S, Kennedy J, Henderson G.

Ecancermedicalscience. 2012;6:245. doi: 10.3332/ecancer.2012.245. Epub 2012 Feb 28.


Gastrointestinal and Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs.

Al-Saeed A.

Oman Med J. 2011 Nov;26(6):385-91. doi: 10.5001/omj.2011.101.


Indigenous anti-ulcer activity of Musa sapientum on peptic ulcer.

Prabha P, Karpagam T, Varalakshmi B, Packiavathy AS.

Pharmacognosy Res. 2011 Oct;3(4):232-8. doi: 10.4103/0974-8490.89742.


A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity.

Conaghan PG.

Rheumatol Int. 2012 Jun;32(6):1491-502. doi: 10.1007/s00296-011-2263-6. Epub 2011 Dec 23. Review.


Interobserver variation in the endoscopic diagnosis of gastroduodenal ulcer scars: implications for clinical management of NSAIDs users.

Amano Y, Uno G, Yuki T, Okada M, Tada Y, Fukuba N, Ishimura N, Ishihara S, Kinoshita Y.

BMC Res Notes. 2011 Oct 13;4:409. doi: 10.1186/1756-0500-4-409.


Safety aspects and rational use of a naproxen + esomeprazole combination in the treatment of rheumatoid disease.

Roberts DN, Miner PB.

Drug Healthc Patient Saf. 2011;3:1-8. doi: 10.2147/DHPS.S7329. Epub 2011 Mar 3.


NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies.

Wallace JL.

Br J Pharmacol. 2012 Jan;165(1):67-74. doi: 10.1111/j.1476-5381.2011.01509.x. Review.


A prospective study of aspirin use and the risk of gastrointestinal bleeding in men.

Huang ES, Strate LL, Ho WW, Lee SS, Chan AT.

PLoS One. 2010 Dec 29;5(12):e15721. doi: 10.1371/journal.pone.0015721.


Critical appraisal of a fixed combination of esomeprazole and low dose aspirin in risk reduction.

Vachhani R, Bouhaidar D, Zfass A, Sandhu B, Nawras A.

Ther Clin Risk Manag. 2010 Jun 24;6:287-92.


Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.

Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, Conaghan PG; National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group.

BMJ. 2009 Jul 14;339:b2538. doi: 10.1136/bmj.b2538.


Discrepancy among observational studies: example of naproxen-associated adverse events.

Rahme E, Lafrance JP, Nedjar H, Rahme G, Morin S.

Open Rheumatol J. 2009 Jan 9;3:1-8. doi: 10.2174/1874312900903010001.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk